Global private equity and venture capital news and research

Posts Tagged ‘biotech’

30 July 2014

Vaccine company PaxVax secures $62m

vaccc Venture capital-backed specialty vaccine business PaxVax has secured a $62m investment including a debt package of $50m from Pharmakon Advisors.

18 July 2014

Biotech startup InflaRx closes Series B round

clinical development Biotech startup InflaRx has closed its Series B round, which reached the “double digit million Euro space.”

18 July 2014

Roka Bioscience raised $60m via Nasdaq IPO

biotech Venture capital-backed molecular diagnostics specialist Roka Bioscience has raised $60m via an IPO on the Nasdaq exchange.

17 July 2014

New Science Ventures hits $20m mark for third fundp

pocket money Venture capital firm New Science Ventures has raised more than a fifth of the $100m target for its third fund, AltAssets can reveal.

8 July 2014

SV Life Sciences hires ex-Edison Ventures general partner Balmuth

balmuth SV Life Sciences has hired experienced venture capital investor Michael Balmuth as a partner in its healthcare services team not long after adding three new venture partners to its biotechnology investment division.

26 June 2014

NVCF provides $10m to support Versant’s Canadian expansion

kanada Venture capital firm Northleaf Venture Catalyst Fund has provided $10m to Versant to fund the healthcare-focused venture capital firm’s expansion in Canada.

20 June 2014

Clarus Ventures raises more than $200m for third fund

clarus Life sciences-focused venture firm Clarus Ventures has hit the $200m mark for its $375m-targeting third fund, according to a document filed with US securities regulators.

20 June 2014

Venture capital-backed Zafgen secures $96m via IPO

obb Venture capital-backed biopharmaceutical company Zafgen has raised $96m via its IPO on the Nasdaq exchange.

13 June 2014

New Science secures first commitments for $100m-targeting third fundp

ny Venture capital firm New Science Ventures is seeking $100m for its third fund, AltAssets can reveal.

6 June 2014

Biotech investment stutters after uptickp

After a brief uptick last month, private equity, venture capital and development capital investment activity targeting biotech companies weakened in May, but the decrease was not as severe as at the beginning of the year.

Page 1 of 1012345...10...Last »

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014